The drug is at the stage of clinical trials of the 1st phase. We have resources for their implementation.
For entry into the market, it is necessary to conduct:
Clinical trials of the 2nd phase (randomized controlled trial with assessment of the drug safety and efficacy compared to the reference drug);
Clinical trials of the 3rd phase (randomized controlled multicentre trial involving a large population of patients);
Marketing stage - entry of the drug into the market on indications of prevention of deep vein thrombosis and pulmonary embolism after knee or hip replacement surgeries;
Post-registration stage - continuation of clinical trials (the 4th phase) with the aim of expanding indications of use (prevention of thrombosis in atrial fibrillation).